Cargando…
CDK4/6 inhibition in luminal breast cancer
Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combination strategies of endocrine therapy with targeted agents are...
Autores principales: | Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Greil, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923084/ https://www.ncbi.nlm.nih.gov/pubmed/27429659 http://dx.doi.org/10.1007/s12254-016-0268-2 |
Ejemplares similares
-
ASCO 2018 highlights: metastatic breast cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018) -
SABCS 2016: systemic therapy for metastatic breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017) -
Cure in metastatic breast cancer
por: Westphal, Theresa, et al.
Publicado: (2018) -
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018) -
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)